Angelita Rebollo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3014791/publications.pdf

Version: 2024-02-01

25 papers	599 citations	858243 12 h-index	685536 24 g-index
26 all docs	26 docs citations	26 times ranked	1116 citing authors

#	Article	IF	Citations
1	Isolation of Primary Hepatocytes for Testing Tumor Penetrating Peptides. Methods in Molecular Biology, 2022, 2383, 413-427.	0.4	1
2	PEPscan: A Broad Spectrum Approach for the Characterization of Protein-Binder Interactions?. Biomolecules, 2022, 12, 178.	1.8	1
3	Preclinical Validation of Tumor-Penetrating and Interfering Peptides against Chronic Lymphocytic Leukemia. Molecular Pharmaceutics, 2022, 19, 895-903.	2.3	3
4	Pepscan Approach for the Identification of Proteinâ€“Protein Interfaces: Lessons from Experiment. Biomolecules, 2021, 11, 772.	1.8	4
5	Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma. Pharmaceutics, 2021, 13, 1631.	2.0	8
6	Bifunctional Therapeutic Peptides for Targeting Malignant B Cells and Hepatocytes: Proof of Concept in Chronic Lymphocytic Leukemia. Advanced Therapeutics, 2020, 3, 2000131.	1.6	13
7	Identification of peptides interfering with the LRRK2/PP1 interaction. PLoS ONE, 2020, 15, e0237110.	1.1	10
8	Anti-tumoral Effect of a Cell Penetrating and Interfering Peptide Targeting PP2A/SET Interaction. Folia Medica, 2020, 62, 31-36.	0.2	7
9	New Therapeutic Approach for Targeting Hippo Signalling Pathway. Scientific Reports, 2019, 9, 4771.	1.6	25
10	Interfering peptides targeting proteinâ€“protein interactions: the next generation of drugs?. Drug Discovery Today, 2018, 23, 272-285.	3.2	108
11	Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications. International Journal of Peptide Research and Therapeutics, 2018, 24, 479-488.	0.9	12
12	Identification and characterization of novel enhanced cell penetrating peptides for anti-cancer cargo delivery. Oncotarget, 2018, 9, 5944-5957.	0.8	12
13	Peptides derived from Plasmodium falciparum leucine-rich repeat 1 bind to serine/threonine phosphatase type 1 and inhibit parasite growth in vitro. Drug Design, Development and Therapy, 2018, Volume 12, 85-88.	2.0	19
14	Evaluation of Caspase-9b and PP2AcÎ±2 as potential biomarkers for chronic lymphocytic leukemia. Biomarker Research, 2016, 4, 9.	2.8	2
15	Strategies to stabilize cell penetrating peptides for in vivo applications. Therapeutic Delivery, 2015, 6, 1171-1194.	1.2	38
16	Enhanced serum proteolysis resistance of cell-penetrating peptides. Therapeutic Delivery, 2015, 6, 139-147.	1.2	11
17	Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia. Protein and Peptide Letters, 2015, 22, 539-546.	0.4	12
18	Specific Targeting of Caspase-9/PP2A Interaction as Potential New Anti-Cancer Therapy. PLoS ONE, 2013, 8, e60816.	1.1	28

#	Article	IF	Citations
19	Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. Blood, 2011, 117, 1917-1927.	0.6	38
20	Differential aiolos expression in human hematopoietic subpopulations. Leukemia Research, 2010, 34, 289-293.	0.4	19
21	Corrigendum to â€œCritical function of Ikaros in controlling Aiolos gene expressionâ€•[FEBS Lett. 581 (2007) 1605-1616]. FEBS Letters, 2009, 583, 1554-1554.	1.3	0
22	Differential epigenetic regulation of Aiolos expression in human tumoral cell lines and primary cells. FEBS Letters, 2008, 582, 457-467.	1.3	5
23	The Aiolos transcription factor is up-regulated in chronic lymphocytic leukemia. Blood, 2008, 111, 3225-3228.	0.6	29
24	Use of Penetrating Peptides Interacting with PP1/PP2A Proteins As a General Approach for a Drug Phosphatase Technology. Molecular Pharmacology, 2006, 69, 1115-1124.	1.0	46
25	Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie, 2003, 85, 721-726.	1.3	148